Thus, we found that patients with ER+ tumours expressing a high SLC7A5/SLC3A2 complex correlated with poor outcome after receiving endocrine therapy, suggesting that assessment of these solute carriers’ expression prior to adjuvant treatment could predict patients who are highly likely to fail to obtain a benefit from the endocrine therapy. The gene discussed is SLC3A2; the disease is neoplasm.